Introduction
Significant advances have been made in the study of epigenetic reprogramming associated with specific cancer and tumour subtypes (1) . Much t of the focus has been on DNA methylation reprogramming or alterations in the post translation modifications (PTM) of DNA bound histone proteins such as tri-methylation at lysine 27 on Histone H3 (H3K27me3) (2, 3) . The identification of several new forms of modified cytosine in vertebrate DNA has added to this narrative by providing new patterns for interpretation, hypothesis building and functional outcomes (4) . In particular, 5-hydroxymethlycytosine (5hmC), generated from a 5-methylcytosine (5mC) precursor by the Ten-Eleven-Translocation (TET) enzymes, is hypothesised to be part of a predicted demethylation pathway and that differs significantly in its genomic distributions from that of 5mC (5) (6) (7) (8) . Whilst 5mC tends to be found over heterochromatic and repetitive portions of the genome and has known roles in on April 12, 2016. © 2016 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on April 6, 2016; DOI: 10.1158/0008-5472. CAN-15-1910 the maintenance of transcriptional silencing, 5hmC is more restricted to the bodies of expressed genes, enhancer elements and a cohort of promoter regions in many tissues (8) (9) (10) . Aside from a predicted role as a demethylation intermediate, the functional significance of the 5hmC modification is still largely unknown.
However there is evidence that the genic levels of 5hmC can correlate with the transcriptional activity of the associated genes in tissues whilst low-level direct enrichment of 5hmC over the core of promoters surrounding the transcription start site (TSS) appears to be related to transcriptional silencing events and maintenance of CpG hypomethylation (11) (12) (13) .
Normal 5hmC patterns are dramatically altered in several human cancer types such as melanoma and hepatocellular carcinoma; as well as in cultured cancer cell lines and colon cancer (9, 11, (14) (15) (16) . In previous work, we have identified hypermethylation prone promoters in various human cancer types which overlap with Polycomb regulated gene sets (17) . We speculated that these genes are prone to methylation due to their inactivity in cancer-host tissue and loss of a demethylase activity (2) . A possibility is that 5hmC/Tet enzymes are involved in this process, as loss of Tet activity from such promoters may licence the occurrence of aberrantly hypermethylatyed CpG islands (CGI) in cancer.
Previously we carried out a number of studies investigating the epigenetic perturbations that occur in liver following exposure to the well-studied rodent non-genotoxic carcinogen (NGC), Phenobarbital (PB), to elucidate potential drug induced epigenetic changes that anticipate cellular transformation (13, 18, 19) . PB is an antiepileptic drug which promotes hepatocarcinogenesis in rodents when administered subsequent to an initiating carcinogen such as N-nitrosodiethylamine (DEN) (20) . This results in selective clonal outgrowth of cells harbouring activating mutations in the proto-oncogene Ctnnb1, encoding β-Catenin, a key mediator in the canonical Wnt signaling pathway (21) . In this study we attempt to delineate the progression of hepatocarcinogenesis through combined epigenetic (5mC, 5hmC & H3K27me3 patterns) and transcriptomic analysis... Our study tracks the initial epigenetic and transcriptomic perturbations throughout the early stages of toxicological insult and follows them to an 'end-state' that is characteristic of liver tumour formation in three models (21, 22) . As a result we link initial loss of 5hmC at CGI promoters with the occurrence of aberrant hypermethylated CGIs in tumours. This occurs at genes that are repressed in normal liver and remain silent in the resulting tumours, possibly due to the continuous presence of the inactivating mark H3K27me3. 
Materials and Methods

Study material and animal treatment
For full description of mouse strains and treatment regimes, please see supplemental materials and methods.
Methyl and hydroxymethyl DNA immunoprecipitation (MeDIP & hMeDIP)
Genomic DNA was extracted from frozen ground-up samples and fragmented to a range between 300 bp to 1,000 bp in size (Bioruptor, Diagenode) prior to immunoprecipitation with 5hmC (active motif #39769) or 5mC (Eurogentic # BI-MECY-1000) antibodies. For HmeDIP and MeDIP protocols see; (13, 18) . DNA was purified using DNA Clean & Concentrator™ (Zymo Research). 5hmC and 5mC patterns were then generated following dye labelling and hybridisation to promoter specific microarrays -either on 2.1M Deluxe mouse promoter tiling microarrays (Roche Nimblegen) for the control, 12 week PB, Ctnnb1 and Ha-ras tumours or on 1M mouse promoter microarrays (Agilent) for control and NASH hepatocellular carcinoma (HCC) tumour samples.
Genome wide ChIP-sequencing of H3K27me3
25 μg of chromatin was taken for the control liver, a 12 week PB treated liver and a PB exposed liver tumour and H3K27me3 chromatin immunoprecipitation carried out using 4 μg of antibody (Millipore, cat # 07-449) as described previously (23) . Following this, Illumina libraries were prepared by Active Motif (Active Motif) and samples sequenced by HiSeq and mapped against the mouse reference genome (mm9 build). Author Manuscript Published OnlineFirst on April 6, 2016; DOI: 10.1158/0008-5472. CAN-15-1910 platform were generated through poly-A enrichment and sequenced at BaseClear BV (BaseClear, Leiden, the Netherlands). For full methods see supplemental information.
Data Access
All data for this study can be found at the Gene Expression Omnibus (GEO) in the super series GSE77731.
Published mouse liver 5hmC datasets were analyzed from GEO series GSE40540 (13, 19) . Published fetal liver RNAseq data analyzed from GEO samples GSM850909. Mouse embryonic stem cell TET1 genome wide datasets were analyzed from GEO sample GSM611192 .
Results
5-methylcytosine and 5-hydroxymethylcytosine patterns are decoupled during hepatocarcinogenesis progression
As PB is thought to promote carcinogenesis through non-genotoxic mechanisms, epigenetic reprogramming through long term exposure are likely to be an important indicator of liver tumour formation. Our work has shown that mice exposed to tumour promoting doses of PB exhibit changes to both their 5hmC and 5mC liver patterns at the promoter proximal regions of many genes (13, 18, 19) . Here we expand upon these findings to investigate perturbations arising in hepatocellular tumours generated by a DEN/PB regimen ( Supplementary   Fig. S1A ).
Immunohistological staining of sections of mouse liver, following DEN/PB exposure, with antibodies against glutamine synthetase (GS) identify Ctnnb1-mutated hepatocellular tumour-lesions which are dependent on an activated Wnt/β-catenin signalling pathway (Fig. 1A) (24) . Staining with antibodies against 5mC or 5hmC reveals that these Ctnnb1-mutated tumours have reduced signals for both DNA modifications (Fig. 1A) , an observation also reported in several types of human cancer including HCC (16) . DNA modification patterns were directly investigated by immunoprecipitation with specific antibodies towards either 5hmC or 5mC prior to hybridization on high density promoter microarrays with a set of control mouse liver DNAs (n=2) and liver DNAs from mice that had been exposed to phenobarbital in their drinking water for 12 weeks (n=2) or in the excised hepatic tumours from mice which had received PB for 35 weeks (n=3). Analysis of overall Pearson's correlation scores between the samples reveals that the 5hmC pattern is strongly perturbed following drug dosing (and in the tumours), whilst 5mC patterns are largely similar following drug dosing but differ greatly in the tumour samples (Fig. 1B) . This result suggests that a change in 5hmC profiles might precede that of 5mC.
Next we defined differentially hydroxymethylated regions (dHMRs) or differentially methylated regions (dMRs) between the control and PB exposed livers or between the control and tumour samples ( Supplementary Fig. S1B ). Mapping of the resulting dHMRs and dMRs to one of five genomic compartments (inter-genic, promoter distal, promoter proximal, promoter core or intra-genic; Supplementary Fig. S1B ) reveals that genomic regions of epigenetic perturbation are largely distinct for the two modifications.
Following PB exposure both at 12 weeks and in the resulting liver tumours, 5hmC was strongly lost over the promoter proximal and core regions and both reduced and elevated in the bodies of genes ( Supplementary   Fig. S1B ). In contrast, an increased number of 5mC peaks were observed in the tumour samples compared to those exposed to short term PB. Additionally, although 5mC was seen to be both acquired and lost at intergenic and intragenic loci following 12 week PB exposure, hypo-methylation was typically observed at such sites in the resulting tumours.
Tumour specific promoter hyper-methylation occurs after phenobarbital mediated loss of 5hmC
As the 5hmC modified DNA is itself derived from TET oxidised hydroxylation of a 5mC precursor, we set out to test the relative changes in both marks across all of the promoters. Firstly, we identified a subset of promoter core regions are marked by 5hmC in the normal livers in this study (Fig. 1C) . Independent validation of select loci by glucosylation-mediated restriction enzyme sensitive qPCR (gRES-qPCR; see supplementary experimental procedures) reveals that these sites contain ~15% to 20% 5hmCpG, whilst a control region of low 5hmC and 5mC at Gapdh was only found to contain less than 5% 5hmCpG ( Supplementary Figs. S2 & S3) .
Analysis of the DNA modification patterns reveal that there is a dramatic loss in promoter core 5hmC levels in the livers of mice exposed to PB for 12 weeks as well as in the resulting tumours (Supplementary Table S1 ).
Extension of this analysis with published liver datasets from mice receiving different lengths of PB dosing reveals that loss of promoter core 5hmC does not occur following acute drug exposure (i.e. 1/7 days) but instead requires longer chronic exposure (i.e. 28days dosing; Supplementary Fig. S6 ) (19) . A reciprocal 5hmC loss/5mC accumulation was also observed at a common set of promoter elements in the PB exposed tumour samples (n=2037), indicating that such a "switch" may be a hallmark of hepatocarcinogenesis progression ( Fig.   1E and 1F).
Promoter hypo 5hmC/hyper 5mC is a common feature of mouse liver tumour types with differing activating mutations
To test if the promoter core loss of 5hmC and gain of 5mC is a feature of chemical exposure or is instead a more general hallmark of hepatocarcinogenesis, we also profiled 5hmC and 5mC patterns in two mouse liver tumours of differing pathology ( Supplementary Fig. S7 ). One was a mouse liver tumour that had arisen following DEN induction only, resulting in a Ha-ras mutated tumour (22) . The second set of liver tumours resulted from an obesity based mouse model in which neonatal male mice develop multiple HCC's following non-alcoholic steatohepatitis (NASH) onset (21) . In both cases we observed a gain of promoter core 5mC at loci normally marked by 5hmC in the healthy tissue ( Fig 1G & Supplementary S7 ). The reciprocal nature of the changes in 5hmC/5mC persist to some degree in all of the three tumour types with a general loss of 5hmC accompanied by a gain in 5mC (Supplementary Figs. S7 & S8). While there was a large degree of commonality in the promoter core spanning probes which exhibited a loss of 5hmC or gain of 5mC between the three tumour types, there were also a number of regions which were unique to the particular tumour type which may reflect stratification of particular cancer subtypes ( Supplementary Fig. S9 ). Author Manuscript Published OnlineFirst on April 6, 2016; DOI: 10.1158/0008-5472. CAN-15-1910 In order to test the relationship between promoter core epigenetic dysregulation and transcriptional perturbation during f hepatocarcinogenesis progression, we carried out RNA-sequencing on matched control livers (n=2), PB treated livers (n=2) and DEN/PB induced Ctnnb1 mutated liver tumour samples (n=3). Pearson correlation analysis and principal component analysis (PCA) reveals that the global transcriptomic patterns of the Ctnnb1 mutated tumours were distinct from both control and PB treated liver ( Supplementary Fig. S10 ).
Promoter epigenetic dysregulation events
No clear relationship was evident between changes in the epigenetic state at promoter core elements with expression alterations of the associated genes ( Fig. 2A) . This was most notable at the promoters of genes exhibiting no significant change in gene expression following PB exposure or in the resulting tumours (grey plots Fig. 2A ). However there is a significant retention of 5hmC levels over the promoter cores of the genes that are repressed in the tumour samples (Fishers P-value 1.99E-0.7) and a reduction of 5mC levels over tumour induced genes (Fishers P-value 2.52E-0.15); implying that there may be a functional relationship between epigenetic and transcriptomic perturbations in the progression of hepatocarcinogenesis (Fig. 2B) . A handful of genes exhibit a strong epigenetic remodelling associated with transcriptional activation , in particular the Cytochrome P450 genes Cyp2b10 and Cyp2c55, which in addition to being two of the most strongly induced genes following PB exposure undergo a strong loss of both promoter core 5hmC and 5mC following PB exposure (Fig. 2C ). In agreement with recent research, the genes which were identified as containing promoter core elements which lost 5hmC and gained 5mC upon tumorigenesis correspond to low expressed/transcriptionally silent genes in the healthy control liver (Fig. 2D ) -highlighting that aberrant methylation at these loci is not directly linked to a change in their transcriptional status in the tumour (17) .
Key signalling pathways are perturbed during hepatocarcinogenesis progression
We next identified differentially expressed genes that arise following PB exposure (control to PB) or upon tumour formation (control to tumour) (>log 2 2 fold change with associated unadjusted P-values <0.05). Genes exhibiting a change in their gene expression patterns were grouped into one of six classes ("i" to "vi", Fig. 3A and 3B, & Supplementary Table S2) based on their profile in control, PB treated and the tumours. Functional analysis of the genes in each class reveals that distinct pathways are de-regulated following PB exposure as well as in the PB exposed liver tumours (Fig 3. B) . For example genes de-regulated exclusively in the Ctnnb1- mutated tumours are linked to pathways involved in production of cell adhesion molecules, diabetes, PPAR signalling and TGF-beta signalling pathway. As well as genes frequently mutated or transcriptionally perturbed in the progression of many cancers (such as the Wnt signalling protein axin1 and the cell cycle regulator ccnd1) (25, 26) . Close inspection of the data reveals strong changes in the expression of genes related to control of proliferation (Cdkn1a), apoptosis and DNA damage response (Trp53 & Gadd45b), as well as genes associated with known cancer related signalling pathways (the Tfg-α gene, the Tgf-β pathway related tumour suppressor, Chd1 and the Wnt signalling component, Ctnnb1 ). In addition we observe strong PB specific responses at select genes previously reported to exhibit transcriptional changes following toxicological challange (Gtl2, Prom1 & Cytochrome P450 genes) (Fig. 3C ). Together this data highlights progressive transcriptomic missregulation that is indicative of physiological changes and a detoxification response.
We also observed specific expression of a series of genes in the tumour samples normally associated with fetal liver (Fig. 3D) . For example α-fetoprotein 1 (Afp1) and Glypican-3 (Gpc3), as well as the hepatocyte nuclear factors 1a, 1b and 4a (Hnf1a, 1b & 4a), are highly expressed in the developing fetal liver compared to the mature adult tissue, whist there is reduced expression of albumin (Alb) and CCAAT/enhancer-binding protein alpha (C/EBPa), which are normally found in the adult liver (Fig. 3D ). This may represent either a dedifferentiation of mature hepatocytes into a more fetal like state or positive selection of liver cancer stem cells during tumorigenesis -which would have a potential growth advantage due to their elevated proliferative abilities (27) . Similar changes were also observed in published expression array datasets for both PB exposed (Ctnnb1 mutated) and non-PB exposed (Ha-ras mutated) liver tumours (Fig. 3E) (28) . (Fig. 4A and Supplementary Fig. S11 ).
Focussing on promoter core regions we find that these are relatively unchanged in response to PB but elevated in the resulting tumour (Fig. 4B) . Studies suggest that promoter regions marked by H3K27me3 in mouse embryonic stem cells become hyper-methylated upon mammary cancer formation (32) . To test this possibility in our mouse liver tumour we directly compared our H3K27me3 and 5hmC/5mC datasets. Plots of promoter core 5hmC and 5mC change against changes in the H3K27me3 signal following PB exposure reveal little change in the histone modification, even though 5hmC levels are lost at a number of loci (Fig. 4C) .
However, compared to the normal genomic profile there is a strong increase in the number of hyperH3K27me3 peaks at promoter spanning loci upon tumour progression. Interestingly a significant proportion of promoters acquire 5mC without a change in H3K27me3 occupancy (Fig. 4C) . Interestingly we observe only a very modest elevation of the H3K27me3 mark at promoters following PB exposure but a strong elevation in signal is observed at many promoters in the resulting tumours (Fig. 4D & Supplementary Fig. S12 ). Promoters (Figs. 4D, 4E & Supplementary Fig. S12 ).
To further test the chromatin landscape of this promoter set in normal control livers we analysed the profiles of several other commonly studied histone tail modifications using publically available mouse liver epigenomics datasets produced by the ENCODE project (http://www.genome.gov/encode/) (Fig. 4F) . Although there was no observable difference, compared to the total promoter set, in the levels of Histone H3 lysine 4 mono-methylation (H3K4me1), H3 lysine 27 acetylation (H3K27ac) or H3 lysine 36 tri-methylation (H3K36me3), there was an enrichment at these promoters for the typically euchromatic mark H3 lysine 4 tri-methylation (H3K4me3). This suggest that a proportion of these 5hmC marked promoters are bivalent (simultaneously enriched for H3K4me3 and H3K27me3).Combined analysis of the promoters which lose 5hmC and gain 5mC in the tumours (n=2035) reveals that a strong epigenetic transition occurs during hepatocarcinogenesis at promoter core elements originally bivalent/5hmC marked and transcriptionally silent genes in the normal healthy liver, without leading to expression changes (Fig. 4G & Supplementary Figs. S13 & S14) .
Tet1 protein levels are reduced in mouse HCC
In order to better understand the epigenetic dysregulation occurring during hepatocarcinogenesis we investigated the transcriptomic changes in a selection of key epigenetic modifying enzymes (Fig 5A) . In general, the majority did not exhibit a strong change in gene expression (>2 fold change vs control tissue). We did, however, observe a strong induction of the histone H3 lysine 9 demethylase Jmjd1c and the histone deacetylase Hdac11 alongside a low to moderate elevation (1.5-2 fold) of several HDACs, methyl-binding proteins (Mbd1), Trithorax (Mll3) and polycomb group proteins (Suz12). The levels of the methyltransferases Dnmt-1 (1.64 FC), -3a (1.51 FC) and -3b (0.98 FC) were not significantly altered. We did not observe changes in levels of expression of the Tet genes (Tet1, 2 and 3) responsible for conversion of 5hmC from 5mC. This result was validated both by microarray and RT-qPCR; thus loss of 5hmC in mouse HCC cannot be explained by the mis-expression of the Tet genes (supplementary Fig. S15) (14, 19, 33) . As levels of the Tet1 protein were previously shown to be reduced in human HCC, we carried out immunohistochemistry for Tet1 in mouse liver tumours (16) (Fig. 5B ). In agreement with the results of the human study, we did observe a strong loss of Tet1 staining in MAPK positive tumour cells. Although levels of Tet1 expression in the mouse liver are low (supplementary Fig. S15 ), this result indicates that protein levels are readily detectable in the normal healthy liver tissue. Published in vitro studies have shown that loss of Tet1 is coincident with loss of 5hmC from promoter regions (9, 34, 35) . Moreover in human embryonic carcinoma NCCIT cells Tet1 loss was seen to correlates with hypermethylation of CGIs and CpG island shores (9) . Interestingly analysis of Tet1 binding sites in published mESC data reveals an enrichment over the promoters that we identify as becoming aberrantly hypermethylated in mouse liver tumours (Supplementary Fig. S16 ). To test for the consequences resulting from loss of the Tet1 protein observed in the liver tumours, we profiled 5hmC levels across the promoter (36) . This revealed that loss of Tet1 in the mouse liver results in a dramatic reduction of 5hmC over a large number of promoters (Fig. 5C ). This was also observed over the promoter regions identified as becoming aberrantly methylated following a loss of 5hmC during tumorigenesis (Supplementary Fig. S17 ) -suggesting that direct reduction in Tet1 protein levels or inhibition of TET activity during the progression of tumorigenesis could account for a decrease of promoter associated 5hmC and enable subsequent gain of 5mC.
Discussion
DNA methylation reprogramming has been previously noted for a host of tumour types including HCC (2, 14, 16, 37) . In addition, changes to the normal 5hmC patterns have also been reported in both mouse and rat livers following exposure to either non-genotoxic or genotoxic agents (13, 19, 38) . In this present study we build on these early observations to show for the first time in mouse models of liver cancer that early perturbations in the epigenetic landscape over transcriptionally silent CGIs that are marked by low levels of 5hmC and H3K27me3.predicate hyper-methylation that occurs in tumours. We utilised several models of rodent liver tumour models (PB exposed Ctnnb1 mutant tumours, DEN treated Ha-Ras mutant tumours and NAFLD driven tumours) to demonstrate the same observation for each. The reciprocal nature of these changes fits with the notion that these two modifications exist within a programmed DNA methylation/demethylation pathway that is mediated by Tet enzyme activity (39). A reduction of Tet1 protein levels in mouse HCC may account for the observed epigenetic disruption, however this occurs without obvious changes in Tet transcript levels (Figs. 1 & 5) . We propose that reduced Tet1 binding and/or activity at target CGIs may be responsible for aberrant epigenetic events in many cancers (Fig. 5D ). Direct loss of Tet1 function in liver results in a similar dramatic reduction in promoter 5hmC levels (Fig. 5C ). In PB exposed mice reduction of Tet1 and 5hmC levels may also be linked to an elevated rate of proliferation in tumour cells and altered cellular intermediary metabolism Author Manuscript Published OnlineFirst on April 6, 2016; DOI: 10.1158/0008-5472. CAN-15-1910 Emerging data suggest that the deregulation of normal Polycomb group proteins (PcG), critical mediators of the "silencing" chromatin modification H3K27me3, plays causative roles in oncogenesis (31, 43) . EZH2 is often highly expressed in HCC and can have important roles in tumour progression and fetal liver development (44). H3K27me3 profiling during mouse PB exposure implies that an "epigenetic switch" takes place at the promoters of genes which are linked to changes in their expression levels during hepatocarcinogenesis; gains in H3K27me3 are associated with repression of genes in the tumours, while loss is accompanied with their activation (Fig. 4D & 4E) . In contrast at the promoters which exhibit aberrant hypermethylation/hypo-hydroxymethylation in the liver tumours, we observe a strong enrichment of H3K27me3 levels in the healthy tissue, which is not significantly altered in the tumours (Figs. 4C, 4D & 4G) . Fittingly these promoters tend to be associated with transcriptionally silent genes -a result which matches with observations in human cancers (17) . These findings are also in line with recent reports in which H3K27me3 modified histone tails were found to be associated with 5mC marked DNA in cultured cancer cells (45,46). Our data builds on previous work which indicated that promoters that are marked with H3K27me3 in embryonic stem cells are more likely to gain DNA methylation during differentiation and carcinogenesis than those lacking H3K27me3 (47,48). We suggest that Tet1 binding along with PRC2 components mark promoters that are destined to become hypermethylated in cancer, this can be inferred by the presence of 5hmC at these regions in control liver samples. Similar findings have been published in human cancer cell lines where promoters marked by H3K27me3 and H3K4me3 were initially enriched for 5hmC but lose this modification upon depletion of Tet1 by siRNA (9) . The finding that 5hmC and H3K27me3 marked promoters mark sites which later become hypermethylated in the tumours supports a model in which general aberrant methylation at CGIs is not linked with silencing of tumour-suppressor-genes, but instead indicates a de-coupling of TET function from PRC2 complexes at these genes. These relationships between DNA and H3K27 methylation clearly warrant more careful molecular examination in vivo, especially as culturing of somatic cells in vitro leads to a reduction in Tet levels and subsequent de novo methylation at H3K27me3 marked promoters (42).
A recent study in human colon cancer reports that promoter proximal regions ~1kb upstream of the TSS marked by 5hmC in the normal colon appear to correlate to sites which is resistant to hypermethylation in colon cancer progression. These results contrast with both our findings and recent observations in mouse mammary tumours and human embryonic carcinoma cells (9, 32) 
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